Navigation Links
Driver of anthrax toxicity could lead to late-stage therapy

A study in the March 24 Cell reports the discovery of a gene that drives anthrax bacteria's toxic effects. The gene could offer a potential new target for countermeasures against the lethal toxin, according to the researchers.

Such therapies might have the potential to protect against anthrax during the late stages of the disease, after antibiotics have lost their therapeutic value, they added.

The team found that human cells deficient in the so-called LDL receptor-related protein (LRP6) become resistant to anthrax toxin. Furthermore, antibodies against LRP6 protected cells from anthrax toxicity, reported study authors Wensheng Wei and Stanley Cohen of the Stanford University School of Medicine in collaboration with others at Stanford and the National Institutes of Health. The level of anthrax protection afforded by the antibodies rose with increasing dose.

Anthrax is a lethal disease of humans and other animals caused by the spore-forming bacteria Bacillus anthracis, which has been the focus of biological interest and bioterrorism concern. The virulence of the bacteria depends on separate complexes formed by interaction of a carrier protein, protective antigen, with lethal and edema factors responsible for the toxic effects and swelling that impairs the host's immune response.

In the current study, the researchers inactivated genes randomly in human cells. They then examined the mutated cells for resistance to anthrax toxin in an effort to identify host genes that have important roles in infection, with the hope of finding possible new targets for therapies aimed at the host instead of the bacteria. The method allows for the identification of required host cell genes without pre-conceptions about their potential to play a role, the study authors said.

The study revealed that LRP6 acts as a co-receptor, enabling cells to take up anthrax toxin through its interactions with two distinct cell- surface proteins earlier shown to bi
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Scientists seek answers on what activates deadly anthrax spores
2. Antibodies from plants protect against anthrax
3. Defensins neutralize anthrax toxin
4. Critical step traced in anthrax infection
5. US Army plans to bulk-buy anthrax
6. New antibody shows promise as cure for anthrax
7. Effective, safe anthrax vaccine can be grown in tobacco plants
8. UCSD study finds anthrax toxins also harmful to fruit flies
9. Scientists design potent anthrax toxin inhibitor
10. Newly discovered protein kills anthrax bacteria by exploding their cell walls
11. Combating anthrax: Results of study published this month as researchers look for a better vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Driver anthrax toxicity could lead late stage therapy

(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... of the 1962 Nobel Prize with Francis Crick and Maurice ... DNA, will present "Curing Incurable Cancer" and attend other events ... the James Graham Brown Cancer Center at the University of ... 5, at the Brown Theater, 315 W. Broadway, Louisville. Admission ...
... early stages of a major cause of failure in joint ... avoid additional surgery. More than 1.5 million total joint replacement ... is 90 per cent, almost 10 per cent of implants ... journal Molecular Pharmaceutics . Dong Wang and colleagues ...
... do not rely on oxygen may have played an important ... to a theory that UChicago researcher Albert Colman is testing ... Siberia. He has found that bacteria at the site ... that scientists must take into account as they attempt to ...
Cached Biology News:UofL hosts address by Nobel Laureate, DNA structure co-discoverer James Watson 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
(Date:5/21/2015)... NEW YORK , May 21, 2015  Prima ... biotechnology company that is striving to become a leader ... of cancer, recently announced that the final CVac data ... has shown a clear trend for a clinically meaningful ... ("SOC") in second remission patients. In the ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... DUBLIN , May 20, 2015 Research ... announced the addition of the "2015 Global ... to their offering. The primary goal ... of flow cytometry instruments and reagents. Key information ... drive the selection of flow cytometers, predominantly used ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
...
... analysis & visualization software. ... multiple samples. Combine Sequest ... increased confidence. Get more ... from your MS/MS experiments.14 ...
Biology Products: